Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 1857-1862

  Raynaud, Florence I ^a   Boxall, Frances E ^a   Goddard, Phyllis ^a   Barnard, Christopher F ^b   Murrer, Barry A ^b   Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

Author keywords

Biotransformation; In vivo activity; Platinum JM216

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; JM 383; JM 518; PLATINUM AMMINE CYCLOHEXYLAMINE DICHLORIDE; SATRAPLATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG TRANSFORMATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; ORGANOPLATINUM COMPOUNDS; PLASMACYTOMA; PROTEIN BINDING; SERUM ALBUMIN; SERUM GLOBULINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029758018     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Calvert AH, Harland SJ, Newell DR, Siddik ZH and Harrap KR: Phase I sudies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 12(suppl A): 51-57, 1985.
2. Peckham MJ, Horwich A, Brada M., Drury A, and Hendry WF: Cisdiammine 1,1-cyclobutane dicarboxylate platinum II (Carboplatin) in the treatment of testicular germ cells tumors: a preliminary report. Cancer Treatment Res 11: 101-110, 1991.
3. Wiltshaw E, Kroner T: Phase II study of cisdichlorodiam-mineplatinumll in advanced adenocarcinoma of ovary. Cancer Treat Rep 1: 55-60, 1976.
4. Giandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Barnard CFJ, Harrap KR, Goddard PM, Kelland LR and Morgan SE: Synthesis and reactions of a new class of orally active Pt (IV) antitumour complexes. In: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. S.B. Howell ed, Plenum Press, New York, USA, pp 93-100, 1991.
5. Kelland LR, Murrer BA, Abel G and Harrap KR: Structure-activity relationship in a series of novel platinum (II) and platinum (IV) ammine/amine complexes evaluated against a panel of human ovarian carcinoma cell lines. J Cell Pharmacol 2: 331-342, 1991.
6. Kelland LR, Abel G., McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA and Harrap, KR: Preclinical Antitumor Evaluation of Bis-acetato-ammine-dichloro-cyclohexylamine Platinum (IV): an orally Active Platinum Drug. Cancer Res 53: 2581-2586, 1993.
7. Mellish, KJ, Kelland, LR and Harrap, KR: in vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrisnsic and acquired resistance to cisplatin. Br J Cancer 63: 240-250, 1993.
8. Twentyman PR, Wright KA, Mistry P, Kelland, LR and Murrer BA: Sensitivity to novel platinum compounds of panel of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 53: 2581-2586, 1992.
9. McKeage MJ, Morgan SE, Boxall FE, Murrer BA, Hard GC and Harrap KR: Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. Br J Cancer 67: 996-1000, 1993.
10. McKeage MJ, Boxall FE, Jones M and Harrap KR: Lack of neurotoxicity of oral bisacetatoamminedichlorocyclohexyiamine-platinum IV (JM216) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 53: 629-631 ,1994.
11. McKeage MJ, Raynaud FI, Ward J, Berry C, Odell D, Mistry P, Kelland LR, Santabarbara P, Harrap KR, and Judson IR: Phase I study of orally administered platinum complex (JM216) using a daily × 5 administration schedule. Proc Amer Soc Clin Oncol 13: 337, 1994.
12. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neil C, Ellis P, Kelland LR, Morgan SE, Murrer B, Santabarbara P, Harrap KR and Judson IR: Phase I and pharmacological study of an oral platinum complex JM216: Dose dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol. 36: 451-458 ,1995.
13. Roberts JJ, Knox RJ, Friedlos F and Lydall DA: DNA as the target for the cytotoxic and antitumour action of platinum co-ordination complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin. In: D.C.H. Mc Brien and T.F. Slater (eds), Biochemical mechanisms of platinum antitumour drugs, pp29-64, Oxford: IRL Press Ltd, 1985.
14. Van Der Vijgh WFJ and Klein I: Protein binding of five platinum compounds: comparison of two ultrafiltration systems. Cancer Chemother Pharmacol. 18: 129-132 ,1986.
15. Poon GK, Raynaud FI, Mistry P, Odell DE, Kelland LR, Harrap KR, Barnard CFJ and Murrer BA: Metabolic studies of an orally active anticancer drug by liquid chromatography-electrospray ionisation-mass spectrometry. Journal of Chromatography, 712: 61-66 ,1995.
16. Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CFJ, Murrer BA and Harrap K.R: Metabolism of JM216 in patients plasma ultrafiltrates. Proc. Am. Assoc. Cancer Res 35: 2586, 1994.
17. Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CFJ, Murrer BA and Harrap KR: Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemotherapy Pharmacology, in Press ,1996.
18. 2 and their reduction products with PM2 DNA. Biochemistry, 23: 4813-4817, 1984.
19. Pendyala L Walsh JR, Huq MM, Arakali AV, Cowens JW and Creaven PJ: Uptake and metabolism of Iproplatin in murine L1210 cells. Cancer Chemother. Pharmacol. 25: 15-18, 1988.
20. Pendyala L, Cowens JW, Chheda GB, Dutta SP and Creaven PG: Identification of Cis-Dichloro-bisisopropyiamineplatinum (II) as a metabolite of iproplatin in humans. Cancer Res 48: 3533-3536, 1989.
21. Pendyala L, and Creaven PJ: In vitro Cytotoxicity, Protein Binding, red Blood cell Partitioning, and biotransformation of Oxaliplatin. Cancer Res 58: 5970-5986, 1993.
22. Yoshida M, Khokhar AR, Zhang YP, Thai G, and Siddik ZH: Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum II and cisplatin in mice bearing FSallC tumors. Cancer Chemother Pharmacol. 35: 38-44, 1994.